Literature DB >> 9840650

3-Aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a porcine model of hemorrhagic shock.

A Szabó1, P Hake, A L Salzman, C Szabó.   

Abstract

Hypoxia, energy deficit, and oxidative damage are principal mechanisms of injury in hemorrhagic shock (HS). Oxidant-induced cellular energetic failure and cell dysfunction is mediated, in part, via the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS). Here we examine the effect of the PARS inhibitor 3-aminobenzamide (3AB) in a severe HS model. Pigs were bled to a cardiac index of 40 mL/kg/min for 2 h, which was followed by saline resuscitation (20 mL/kg). Hypovolemia induced decreases in mean arterial blood pressure (to 40-42 mmHg), in both atrial pressures, in systemic oxygen consumption (by 26-30%), and in mixed venous saturation (by 65%). HS also caused lactic acidosis (4.0-5.5 mM). Fluid replacement with saline caused only a partial and transient recovery of blood pressure and cardiac output, with no recovery of stroke work during resuscitation. Fluid replacement did not prevent the progressive hemodynamic decompensation. The PARS inhibitor 3AB (15 mg/kg) significantly ameliorated the fall in blood pressure, cardiac output, and stroke work; slightly increased left atrial pressure during resuscitation; and significantly prolonged survival. PARS inhibition also prevented the reduction in oxygen consumption and mixed venous saturation during resuscitation. Taking these data together, we conclude that pharmacological inhibition of PARS exerts beneficial effects in a porcine model of severe HS. We propose that favorable action of 3AB is related, at least in part, to an improved cardiac performance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9840650     DOI: 10.1097/00024382-199811000-00007

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  12 in total

1.  Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.

Authors:  Partha Mukhopadhyay; Béla Horváth; Malek Kechrid; Galin Tanchian; Mohanraj Rajesh; Amarjit S Naura; A Hamid Boulares; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2011-08-17       Impact factor: 7.376

2.  Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock.

Authors:  M C McDonald; H M Filipe; C Thiemermann
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase.

Authors:  L Liaudet; F G Soriano; E Szabó; L Virág; J G Mabley; A L Salzman; C Szabo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  The world according to poly(ADP-ribose) polymerase (PARP)--update 2006.

Authors:  Eberhard Barth; Peter Radermacher; Csaba Szabó
Journal:  Intensive Care Med       Date:  2006-08-23       Impact factor: 17.440

5.  Protective effects of PARP inhibition on liver microcirculation and function after haemorrhagic shock and resuscitation in male rats.

Authors:  J P Roesner; D A Vagts; T Iber; C Eipel; B Vollmar; G F E Nöldge-Schomburg
Journal:  Intensive Care Med       Date:  2006-08-23       Impact factor: 17.440

6.  Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock.

Authors:  M C McDonald; H Mota-Filipe; J A Wright; M Abdelrahman; M D Threadgill; A S Thompson; C Thiemermann
Journal:  Br J Pharmacol       Date:  2000-06       Impact factor: 8.739

7.  Nicotinamide increases systemic vascular resistance in ovine endotoxemia.

Authors:  Marion Scharte; Jerzy-Roch Nofer; Hugo Van Aken; Rene Waurick; Jörg Meyer; Hans-Georg Bone
Journal:  Intensive Care Med       Date:  2003-05-01       Impact factor: 17.440

8.  Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D.

Authors:  Jon G Mabley; Rebecca Wallace; Pál Pacher; Kanneganti Murphy; Csaba Szabó
Journal:  Int J Mol Med       Date:  2007-06       Impact factor: 4.101

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 10.  Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.

Authors:  Pál Pacher; Csaba Szabó
Journal:  Cardiovasc Drug Rev       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.